Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
33
COV.V Quote, Financials, Valuation and Earnings
Last price:
$1.77
Seasonality move
:
3.15%
Day range:
$1.80 - $1.81
52-week range:
$1.78 - $3.75
Dividend yield:
0%
P/E ratio:
24.39x
P/S ratio:
1.53x
P/B ratio:
1.61x
Volume:
14K
Avg. volume:
13K
1-year change:
-46.9%
Market cap:
$49.4M
Revenue:
$32.8M
EPS (TTM):
$0.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COV.V
Covalon Technologies Ltd.
|
$10.5M | -$0.04 | 9.42% | -6.98% | $2.90 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
PCRX.V
PharmaCorp Rx, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COV.V
Covalon Technologies Ltd.
|
$1.80 | $2.90 | $49.4M | 24.39x | $0.15 | 0% | 1.53x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
|
PCRX.V
PharmaCorp Rx, Inc.
|
$0.42 | -- | $50.1M | 280.00x | $0.00 | 0% | 2.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COV.V
Covalon Technologies Ltd.
|
6.83% | 0.762 | 3.91% | 6.16x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
|
PCRX.V
PharmaCorp Rx, Inc.
|
12.59% | 0.009 | 7.72% | 1.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COV.V
Covalon Technologies Ltd.
|
$4.2M | $245.8K | 6.62% | 6.87% | 2.83% | -$847.4K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
|
PCRX.V
PharmaCorp Rx, Inc.
|
$403.2K | -$498.8K | 0.57% | 0.6% | -10.39% | $537.5K |
Covalon Technologies Ltd. vs. Competitors
-
Which has Higher Returns COV.V or COOL.CX?
Core One Labs, Inc. has a net margin of 4.12% compared to Covalon Technologies Ltd.'s net margin of --. Covalon Technologies Ltd.'s return on equity of 6.87% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital COV.VCovalon Technologies Ltd.48.76% $0.01 $33M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About COV.V or COOL.CX?
Covalon Technologies Ltd. has a consensus price target of $2.90, signalling upside risk potential of 61.11%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Covalon Technologies Ltd. has higher upside potential than Core One Labs, Inc., analysts believe Covalon Technologies Ltd. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COV.VCovalon Technologies Ltd.1 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is COV.V or COOL.CX More Risky?
Covalon Technologies Ltd. has a beta of -0.206, which suggesting that the stock is 120.585% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock COV.V or COOL.CX?
Covalon Technologies Ltd. has a quarterly dividend of $0.15 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Covalon Technologies Ltd. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COV.V or COOL.CX?
Covalon Technologies Ltd. quarterly revenues are $8.7M, which are larger than Core One Labs, Inc. quarterly revenues of --. Covalon Technologies Ltd.'s net income of $358.3K is higher than Core One Labs, Inc.'s net income of --. Notably, Covalon Technologies Ltd.'s price-to-earnings ratio is 24.39x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Covalon Technologies Ltd. is 1.53x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns COV.V or CURE.X.CX?
Biocure Technology has a net margin of 4.12% compared to Covalon Technologies Ltd.'s net margin of --. Covalon Technologies Ltd.'s return on equity of 6.87% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital COV.VCovalon Technologies Ltd.48.76% $0.01 $33M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About COV.V or CURE.X.CX?
Covalon Technologies Ltd. has a consensus price target of $2.90, signalling upside risk potential of 61.11%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Covalon Technologies Ltd. has higher upside potential than Biocure Technology, analysts believe Covalon Technologies Ltd. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings COV.VCovalon Technologies Ltd.1 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is COV.V or CURE.X.CX More Risky?
Covalon Technologies Ltd. has a beta of -0.206, which suggesting that the stock is 120.585% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock COV.V or CURE.X.CX?
Covalon Technologies Ltd. has a quarterly dividend of $0.15 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Covalon Technologies Ltd. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COV.V or CURE.X.CX?
Covalon Technologies Ltd. quarterly revenues are $8.7M, which are larger than Biocure Technology quarterly revenues of --. Covalon Technologies Ltd.'s net income of $358.3K is higher than Biocure Technology's net income of --. Notably, Covalon Technologies Ltd.'s price-to-earnings ratio is 24.39x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Covalon Technologies Ltd. is 1.53x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns COV.V or HEAL.CX?
has a net margin of 4.12% compared to Covalon Technologies Ltd.'s net margin of --. Covalon Technologies Ltd.'s return on equity of 6.87% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital COV.VCovalon Technologies Ltd.48.76% $0.01 $33M HEAL.CX-- -- -- -
What do Analysts Say About COV.V or HEAL.CX?
Covalon Technologies Ltd. has a consensus price target of $2.90, signalling upside risk potential of 61.11%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Covalon Technologies Ltd. has higher upside potential than , analysts believe Covalon Technologies Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings COV.VCovalon Technologies Ltd.1 0 0 HEAL.CX0 0 0 -
Is COV.V or HEAL.CX More Risky?
Covalon Technologies Ltd. has a beta of -0.206, which suggesting that the stock is 120.585% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock COV.V or HEAL.CX?
Covalon Technologies Ltd. has a quarterly dividend of $0.15 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Covalon Technologies Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COV.V or HEAL.CX?
Covalon Technologies Ltd. quarterly revenues are $8.7M, which are larger than quarterly revenues of --. Covalon Technologies Ltd.'s net income of $358.3K is higher than 's net income of --. Notably, Covalon Technologies Ltd.'s price-to-earnings ratio is 24.39x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Covalon Technologies Ltd. is 1.53x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K HEAL.CX-- -- -- --
-
Which has Higher Returns COV.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of 4.12% compared to Covalon Technologies Ltd.'s net margin of --. Covalon Technologies Ltd.'s return on equity of 6.87% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital COV.VCovalon Technologies Ltd.48.76% $0.01 $33M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About COV.V or NSHS.CX?
Covalon Technologies Ltd. has a consensus price target of $2.90, signalling upside risk potential of 61.11%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Covalon Technologies Ltd. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Covalon Technologies Ltd. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COV.VCovalon Technologies Ltd.1 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is COV.V or NSHS.CX More Risky?
Covalon Technologies Ltd. has a beta of -0.206, which suggesting that the stock is 120.585% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock COV.V or NSHS.CX?
Covalon Technologies Ltd. has a quarterly dividend of $0.15 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Covalon Technologies Ltd. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COV.V or NSHS.CX?
Covalon Technologies Ltd. quarterly revenues are $8.7M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Covalon Technologies Ltd.'s net income of $358.3K is higher than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Covalon Technologies Ltd.'s price-to-earnings ratio is 24.39x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Covalon Technologies Ltd. is 1.53x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
-
Which has Higher Returns COV.V or PCRX.V?
PharmaCorp Rx, Inc. has a net margin of 4.12% compared to Covalon Technologies Ltd.'s net margin of -8.52%. Covalon Technologies Ltd.'s return on equity of 6.87% beat PharmaCorp Rx, Inc.'s return on equity of 0.6%.
Company Gross Margin Earnings Per Share Invested Capital COV.VCovalon Technologies Ltd.48.76% $0.01 $33M PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M -
What do Analysts Say About COV.V or PCRX.V?
Covalon Technologies Ltd. has a consensus price target of $2.90, signalling upside risk potential of 61.11%. On the other hand PharmaCorp Rx, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Covalon Technologies Ltd. has higher upside potential than PharmaCorp Rx, Inc., analysts believe Covalon Technologies Ltd. is more attractive than PharmaCorp Rx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COV.VCovalon Technologies Ltd.1 0 0 PCRX.VPharmaCorp Rx, Inc.0 0 0 -
Is COV.V or PCRX.V More Risky?
Covalon Technologies Ltd. has a beta of -0.206, which suggesting that the stock is 120.585% less volatile than S&P 500. In comparison PharmaCorp Rx, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock COV.V or PCRX.V?
Covalon Technologies Ltd. has a quarterly dividend of $0.15 per share corresponding to a yield of 0%. PharmaCorp Rx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Covalon Technologies Ltd. pays -- of its earnings as a dividend. PharmaCorp Rx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COV.V or PCRX.V?
Covalon Technologies Ltd. quarterly revenues are $8.7M, which are larger than PharmaCorp Rx, Inc. quarterly revenues of $4.8M. Covalon Technologies Ltd.'s net income of $358.3K is higher than PharmaCorp Rx, Inc.'s net income of -$409.2K. Notably, Covalon Technologies Ltd.'s price-to-earnings ratio is 24.39x while PharmaCorp Rx, Inc.'s PE ratio is 280.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Covalon Technologies Ltd. is 1.53x versus 2.85x for PharmaCorp Rx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
